SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Inhibition of interleukin 6 signalling and renal function: a Mendelian randomization study.

Ryan, DK; Karhunen, V; Walker, DJ; Gill, D (2021) Inhibition of interleukin 6 signalling and renal function: a Mendelian randomization study. Br J Clin Pharmacol, 87 (7). pp. 3000-3013. ISSN 1365-2125 https://doi.org/10.1111/bcp.14725
SGUL Authors: Gill, Dipender Preet Singh Walker, Drew James

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview

Abstract

Inhibition of interleukin 6 (IL-6) signalling has been proposed as a potential cardioprotective strategy for patients with chronic kidney disease (CKD), but the direct effects of IL-6 inhibition on renal function are not known. A Mendelian randomization (MR) study was performed to investigate the association of genetically proxied inhibition of IL-6 signalling with estimated glomerular filtration rate (eGFR), CKD and blood urea nitrogen (BUN). Inverse-variance weighted MR was used as the main analysis, with sensitivity analyses performed using simple median, weighted median and MR-Egger methods. There was no evidence for an association of genetically proxied inhibition of IL-6 signalling (scaled per standard deviation unit decrease in C-reactive protein) with log eGFR (0.001, 95% confidence interval -0.004 - 0.007), BUN (0.009, 95% confidence interval -0.003 - 0.021) and CKD (odds ratio 0.948, 95% confidence interval 0.822 - 1.094). These findings do not raise concerns for IL-6 signalling having large adverse effects on renal function.

Item Type: Article
Additional Information: © 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: Interleukin-6, Mendelian randomisation study, cardiovascular disease, chronic kidney disease, Interleukin-6, Mendelian randomisation study, cardiovascular disease, chronic kidney disease, 1115 Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Journal or Publication Title: Br J Clin Pharmacol
ISSN: 1365-2125
Language: eng
Dates:
DateEvent
28 June 2021Published
10 February 2021Published Online
22 December 2020Accepted
Publisher License: Publisher's own licence
Projects:
Project IDFunderFunder ID
RE/18/4/34215British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
PubMed ID: 33393675
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/112773
Publisher's version: https://doi.org/10.1111/bcp.14725

Actions (login required)

Edit Item Edit Item